Does VERTEPORFIN Cause Choroidal neovascularisation? 47 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 47 reports of Choroidal neovascularisation have been filed in association with VERTEPORFIN (Visudyne). This represents 6.2% of all adverse event reports for VERTEPORFIN.
47
Reports of Choroidal neovascularisation with VERTEPORFIN
6.2%
of all VERTEPORFIN reports
0
Deaths
3
Hospitalizations
How Dangerous Is Choroidal neovascularisation From VERTEPORFIN?
Of the 47 reports, 3 (6.4%) required hospitalization.
Is Choroidal neovascularisation Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for VERTEPORFIN. However, 47 reports have been filed with the FAERS database.
What Other Side Effects Does VERTEPORFIN Cause?
Visual acuity reduced (173)
Off label use (129)
Polypoidal choroidal vasculopathy (128)
Disease progression (115)
Age-related macular degeneration (90)
Retinal haemorrhage (70)
Product use in unapproved indication (57)
Retinal detachment (42)
Subretinal fluid (42)
Detachment of retinal pigment epithelium (36)
What Other Drugs Cause Choroidal neovascularisation?
RANIBIZUMAB (195)
PEGCETACOPLAN (52)
AFLIBERCEPT (47)
BEVACIZUMAB (38)
BROLUCIZUMAB-DBLL (38)
PENTOSAN POLYSULFATE (17)
PREDNISONE (10)
SILDENAFIL (10)
LUCENTIS (9)
AVACINCAPTAD PEGOL (7)
Which VERTEPORFIN Alternatives Have Lower Choroidal neovascularisation Risk?
VERTEPORFIN vs VESICARE
VERTEPORFIN vs VFEND
VERTEPORFIN vs VIAGRA
VERTEPORFIN vs VIBEGRON
VERTEPORFIN vs VICODIN